Hadassah

Placental Stem Cells Prove Successful in Bringing Little Girl to Recovery at Hadassah

Tuesday, May 15 2012

Using placental mesenchymal stem cells--which proved effective in pre-clinical trials--physicians at the Hadassah University Medical Center rescued the life of a seven-year-old Romanian girl whose two bone marrow transplants were not triggering the repair needed to save her life.

“B” was suffering from severe aplastic anemia, a disorder where the bone marrow does not produce sufficient new cells to replenish the blood. For the last 10 months, she had been hospitalized at Hadassah in critical condition. While her body accepted the two transplants from two different donors, the donated bone marrow was unsuccessful in getting her body to take over the replenishment process and produce new red blood cells. Prof. Reuven Or, head of the Sidney Weisner Department of Bone Marrow Transplantation and Cancer Immunology, decided to speak with Prof. Rafi Gorodetsky, Director of Hadassah’s Biotechnology and Radiobiology Laboratory in the Sharrett Institute of Oncology, who was conducting stem cell research sponsored by Pluristem Therapeutics, an Israeli bio-tech company which develops placental mesenchymal cells.  Prof. Gorodetsky's pre-clinical trial showed success in treating radiated mice with the Pluristem cells. (See ”Placental Cells Found to Have Potential to Mitigate Acute Radiation Syndrome,” in www.hadassah.org/hmedicine, October 2011.)

After receiving the approvals of Hadassah's Helsinki Committee and Israel’s Ministry of Health, Hadassah’s physicians gave “B” two shots of the Pluristem cells, injecting them into her thigh muscle. The recovery was so significant that “B” was able to leave the hospital.

"This is a moment every physician and researcher waits for," says Prof. Or. "We now have a new tool and I always prefer to use biological substance over chemical components." Prof. Or cautions, however, that this is only one single case and 
the treatment still requires full scientific exploration and validation. Scientists at Pluristem and Prof. Or will now discuss “next steps” and how to widen the scope of their studies.

“Whatever happens next,” comments Ron Krumer, Director of Hadassah’s External Relations Department, “we can enjoy another story of life saving at Hadassah--a combination of the ingenuity of an Israeli biotech firm, Hadassah research, and Hadassah clinical excellence.”

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Nov 14 2017

Abraham and Sarah — and a Modern-Day Miracle Baby

They're not quite Matriarch Sarah and Patriarch Abraham, who were 90 and 100, respectively, when their son, Isaac, was born. This couple--she’s 48 and he is 62--are parents of a baby boy, thanks to a hand from heaven and the team at Hadassah Hospital Mount Scopus.

READ MORE ›
alt_text

Thursday, Nov 9 2017

New NICU at Hadassah: First of Its Kind in Israel

Tiny patients with big problems are now being treated in the new Neonatal Intensive Care Unit (NICU) at Hadassah Hospital Ein Kerem—the first of its kind in Israel.

READ MORE ›
alt_text

Monday, Oct 30 2017

Hadassah Hospital Metrics on the Rise

HMO By The Numbers

READ MORE ›
alt_text

Tuesday, Oct 24 2017

Hadassah Doctor Brings New Hope to Cystic Fibrosis Patients

Twenty five years ago, Dr. Batsheva Kerem and Dr. Eitan Kerem made a significant contribution to the scientific world’s understanding of genetic mutations and cystic fibrosis.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More